These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 20671769)

  • 1. Osteosarcoma cells as carriers to allow antitumor activity of canine oncolytic adenovirus in the presence of neutralizing antibodies.
    Alcayaga-Miranda F; Cascallo M; Rojas JJ; Pastor J; Alemany R
    Cancer Gene Ther; 2010 Nov; 17(11):792-802. PubMed ID: 20671769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
    Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent.
    Gentschev I; Stritzker J; Hofmann E; Weibel S; Yu YA; Chen N; Zhang Q; Bullerdiek J; Nolte I; Szalay AA
    Cancer Gene Ther; 2009 Apr; 16(4):320-8. PubMed ID: 18949014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
    Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
    J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models.
    Ganesh S; Gonzalez-Edick M; Gibbons D; Van Roey M; Jooss K
    Clin Cancer Res; 2008 Jun; 14(12):3933-41. PubMed ID: 18559615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic Semliki forest virus vector as a novel candidate against unresectable osteosarcoma.
    Ketola A; Hinkkanen A; Yongabi F; Furu P; Määttä AM; Liimatainen T; Pirinen R; Björn M; Hakkarainen T; Mäkinen K; Wahlfors J; Pellinen R
    Cancer Res; 2008 Oct; 68(20):8342-50. PubMed ID: 18922906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
    Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
    Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous injection of irradiated tumor cell vaccine carrying oncolytic adenovirus suppressed the growth of multiple lung tumors in a mouse squamous cell carcinoma model.
    Saito A; Morishita N; Mitsuoka C; Kitajima S; Hamada K; Lee KM; Kawabata M; Fujisawa M; Shirakawa T
    J Gene Med; 2011 Jun; 13(6):353-61. PubMed ID: 21674738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery.
    Rojas LA; Condezo GN; Moreno R; Fajardo CA; Arias-Badia M; San Martín C; Alemany R
    J Control Release; 2016 Sep; 237():78-88. PubMed ID: 27388756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Boosting oncolytic adenovirus potency with magnetic nanoparticles and magnetic force.
    Tresilwised N; Pithayanukul P; Mykhaylyk O; Holm PS; Holzmüller R; Anton M; Thalhammer S; Adigüzel D; Döblinger M; Plank C
    Mol Pharm; 2010 Aug; 7(4):1069-89. PubMed ID: 20550160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
    Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
    Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic virus therapy for pancreatic cancer using the adenovirus library displaying random peptides on the fiber knob.
    Nishimoto T; Yoshida K; Miura Y; Kobayashi A; Hara H; Ohnami S; Kurisu K; Yoshida T; Aoki K
    Gene Ther; 2009 May; 16(5):669-80. PubMed ID: 19225547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity.
    Barton KN; Paielli D; Zhang Y; Koul S; Brown SL; Lu M; Seely J; Kim JH; Freytag SO
    Mol Ther; 2006 Feb; 13(2):347-56. PubMed ID: 16290236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
    Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
    Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
    Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
    Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy.
    Han ZQ; Assenberg M; Liu BL; Wang YB; Simpson G; Thomas S; Coffin RS
    J Gene Med; 2007 Feb; 9(2):99-106. PubMed ID: 17256802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fusion of the BCL9 HD2 domain to E1A increases the cytopathic effect of an oncolytic adenovirus that targets colon cancer cells.
    Fuerer C; Homicsko K; Lukashev AN; Pittet AL; Iggo RD
    BMC Cancer; 2006 Oct; 6():236. PubMed ID: 17020613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma.
    De Maria R; Miretti S; Iussich S; Olivero M; Morello E; Bertotti A; Christensen JG; Biolatti B; Levine RA; Buracco P; Di Renzo MF
    J Pathol; 2009 Jul; 218(3):399-408. PubMed ID: 19402129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma.
    Lamfers ML; Gianni D; Tung CH; Idema S; Schagen FH; Carette JE; Quax PH; Van Beusechem VW; Vandertop WP; Dirven CM; Chiocca EA; Gerritsen WR
    Cancer Res; 2005 Oct; 65(20):9398-405. PubMed ID: 16230403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.